Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)

Citizens JMP analyst Roy Buchanan reiterated a Market Outperform rating and $5.00 price target on AN2 Therapeutics (NASDAQ: ANTX).

The analyst commented, “We hosted Dr. Stephen Ruoss, MD, who is a Professor in Pulmonary and Critical Care and Medical Director and the Clinical Chief of the Pulmonary and Critical Care Divisions at Stanford Medical. Dr. Ruoss has approximately two decades of experience in treating NTM and has been an investigator on a number of trials for important therapeutics and candidates, including the Phase 2/3 for epetraborole and the ARISE trial for Arikayce, to name a couple."

Also, "Our call focused on the EBO-301 Phase 2/3 for epetraborole, with Dr. Ruoss being surprised and encouraged by the PRO (patient reported outcome) efficacy results, and disappointed but not surprised by the culture conversion results. Our main takeaway is that Dr. Ruoss views epetraborole as demonstrating We continue to have conviction in the efficacy results on the QOL-B for epetraborole in MAC NTM following our call with Dr. Ruoss. views epetraborole as demonstrating clinically meaningful results for the QOL-B PRO in Phase 2, he expects similar results in Phase 3, and that the candidate can be a meaningful and much needed addition to the treatment paradigm for MAC NTM (and maybe beyond to MAB).”

For an analyst ratings summary and ratings history on AN2 Therapeutics click here. For more ratings news on AN2 Therapeutics click here.

Shares of AN2 Therapeutics closed at $1.14 yesterday.

You May Also Be Interested In

• McEwen Copper seeks $1.6b in equity financing for Los Azules - Bloomberg
• Logansport Financial Corp (LOGN) Declares $.45 Quarterly Dividend; 5% Yield
• SEC proposes new rules for crypto asset investment contracts